Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.
coronary calcification
hemodialysis
vascular calcification
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
22
07
2020
revised:
10
09
2020
accepted:
15
09
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
12
12
2020
Statut:
epublish
Résumé
Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving maintenance hemodialysis. In this analysis, we assessed the efficacy of SNF472 in prespecified patient subgroups. In a randomized clinical trial SNF472 300 mg, SNF472 600 mg, or placebo were infused thrice weekly in 91, 92, and 91 patients receiving maintenance hemodialysis and with CAC at baseline, respectively. In prespecified subanalyses, the percent change in CAC volume score (CACvs) from baseline to week 52 in modified intention-to-treat (mITT) and per-protocol (PP) populations was calculated in the following subgroups: age, sex, diabetes mellitus, dialysis vintage, prior atherosclerotic cardiovascular disease, baseline use of non-calcium and calcium-based phosphate binders, calcimimetics, activated vitamin D, warfarin, and statins. In the main trial, SNF472 significantly reduced CACvs progression compared with placebo (11% versus 20% mITT analyses; SNF472 treatment for 52 weeks reduced CACvs progression compared with placebo in a broad range of patients receiving maintenance hemodialysis. Future studies will determine the impact of SNF472 on cardiovascular events in this population.
Identifiants
pubmed: 33305110
doi: 10.1016/j.ekir.2020.09.032
pii: S2468-0249(20)31548-5
pmc: PMC7710828
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2178-2182Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 International Society of Nephrology. Published by Elsevier Inc.
Références
Nephrol Dial Transplant. 2013 Jan;28(1):146-52
pubmed: 23028103
Radiology. 1998 Sep;208(3):807-14
pubmed: 9722864
Nat Rev Nephrol. 2014 Dec;10(12):732-42
pubmed: 25287433
Kidney Int. 2005 Oct;68(4):1815-24
pubmed: 16164659
Nephrol Dial Transplant. 2011 Apr;26(4):1327-39
pubmed: 21148030
Nat Clin Pract Cardiovasc Med. 2007 Jan;4(1):26-33
pubmed: 17180147
Lancet. 2013 Oct 12;382(9900):1268-77
pubmed: 23870817
Nephrol Dial Transplant. 2006 Nov;21(11):3215-22
pubmed: 16877490
PLoS One. 2018 May 9;13(5):e0197061
pubmed: 29742152
Kidney Int. 2002 Jul;62(1):245-52
pubmed: 12081584
Circulation. 2020 Mar 3;141(9):728-739
pubmed: 31707860
Eur J Clin Invest. 2017 Feb;47(2):137-148
pubmed: 28036114
JACC Basic Transl Sci. 2020 Apr 27;5(4):398-412
pubmed: 32368697
Circulation. 2006 Jan 3;113(1):30-7
pubmed: 16365194